Case Report
Copyright ©The Author(s) 2020.
World J Clin Cases. Feb 6, 2020; 8(3): 594-599
Published online Feb 6, 2020. doi: 10.12998/wjcc.v8.i3.594
Table 3 Selected trials of anti-HER2 agents in advanced bladder cancer
RegimenPhaseNo of patientsPrior chemotherapyTarget enrichmentOR (%)mOS (mo)
Carboplatin/ paclitaxel/ gemcitabine/trastuzmabI/II57NoYes7014.1
LapatinibII59YesNo1.74.5
Lapatinib maintenance after first-line chemotherapyII/III116NoYes1412.6